---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-124081"
form_type: "8-K"
ticker: "ATXI"
cik: "0001644963"
company_name: "AVENUE THERAPEUTICS, INC."
filed_at: "2024-11-29T23:59:59+00:00"
generated_at: "2026-05-29T12:53:08.636814+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Avenue Therapeutics receives Nasdaq delisting notice for equity deficiency; intends to request hearing

## Summary
- Stockholders' equity of $1.652M as of Sep 30, 2024, below Nasdaq's $2.5M minimum requirement.
- Delisting determined due to prior Panel Monitor; company ineligible for 180-day extension submission.
- Trading continues; company must request hearing by Dec 3, 2024, to stay delisting.
- Company believes equity compliance regained per Q3 10-Q Note 9; will demonstrate at hearing.

## SEC filing metadata
- accession: 0001104659-24-124081
- form_type: 8-K
- ticker: ATXI
- cik: 0001644963
- company_name: AVENUE THERAPEUTICS, INC.
- filed_at: 2024-11-29T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1644963/000110465924124081/0001104659-24-124081-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1644963/000110465924124081/tm2429840d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-124081
- JSON: https://secwatch.observer/filing/0001104659-24-124081.json
- Plain text: https://secwatch.observer/filing/0001104659-24-124081.txt

## Key facts
- Listing & Compliance Notices
  AVENUE THERAPEUTICS, INC. received a nasdaq delisting notice notice regarding stockholders equity (rules 5550(b)(1)).
  - Exchange: nasdaq
  - Notice: delisting notice
  - Deficiency: stockholders equity
  - Rules: 5550(b)(1)
  source text: least $2,500,000 (the “Stockholders’ Equity Requirement”). The Company’s Quarterly Report on Form 10-Q for the period ended September 30, 2024 reported stockholders’ equity of $1,652,000. In a decision dated June 3, 2024, a Nasdaq Hearings Panel (the “Panel”) previously had confirmed that the Company regained compliance with the Stockholders’ Equity
  evidence_url: https://www.sec.gov/Archives/edgar/data/1644963/000110465924124081/0001104659-24-124081-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.